JP2015504052A5 - - Google Patents

Download PDF

Info

Publication number
JP2015504052A5
JP2015504052A5 JP2014549601A JP2014549601A JP2015504052A5 JP 2015504052 A5 JP2015504052 A5 JP 2015504052A5 JP 2014549601 A JP2014549601 A JP 2014549601A JP 2014549601 A JP2014549601 A JP 2014549601A JP 2015504052 A5 JP2015504052 A5 JP 2015504052A5
Authority
JP
Japan
Prior art keywords
seq
peptide
domain
fusion protein
gly gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014549601A
Other languages
English (en)
Japanese (ja)
Other versions
JP6324905B2 (ja
JP2015504052A (ja
Filing date
Publication date
Priority claimed from PL397595A external-priority patent/PL223487B1/pl
Application filed filed Critical
Publication of JP2015504052A publication Critical patent/JP2015504052A/ja
Publication of JP2015504052A5 publication Critical patent/JP2015504052A5/ja
Application granted granted Critical
Publication of JP6324905B2 publication Critical patent/JP6324905B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014549601A 2011-12-28 2012-12-22 抗がん融合タンパク質 Active JP6324905B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PLP.397595 2011-12-28
PL397595A PL223487B1 (pl) 2011-12-28 2011-12-28 Przeciwnowotworowe białko fuzyjne
PCT/IB2012/057657 WO2013098755A2 (en) 2011-12-28 2012-12-22 Anticancer fusion protein

Publications (3)

Publication Number Publication Date
JP2015504052A JP2015504052A (ja) 2015-02-05
JP2015504052A5 true JP2015504052A5 (enExample) 2016-02-18
JP6324905B2 JP6324905B2 (ja) 2018-05-16

Family

ID=47716118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014549601A Active JP6324905B2 (ja) 2011-12-28 2012-12-22 抗がん融合タンパク質

Country Status (28)

Country Link
US (1) US20140377216A1 (enExample)
EP (1) EP2797950B1 (enExample)
JP (1) JP6324905B2 (enExample)
KR (1) KR20140110017A (enExample)
CN (1) CN103987728B (enExample)
AU (1) AU2012360086B2 (enExample)
BR (1) BR112014015922A2 (enExample)
CA (1) CA2859494A1 (enExample)
CY (1) CY1120055T1 (enExample)
DK (1) DK2797950T3 (enExample)
EA (1) EA201491277A1 (enExample)
ES (1) ES2655828T3 (enExample)
HR (1) HRP20180012T1 (enExample)
HU (1) HUE035794T2 (enExample)
IL (1) IL232834A (enExample)
LT (1) LT2797950T (enExample)
MX (1) MX352796B (enExample)
NO (1) NO2797950T3 (enExample)
PH (1) PH12014501363A1 (enExample)
PL (2) PL223487B1 (enExample)
PT (1) PT2797950T (enExample)
RS (1) RS56758B1 (enExample)
SG (1) SG11201403282QA (enExample)
SI (1) SI2797950T1 (enExample)
SM (1) SMT201800026T1 (enExample)
UA (1) UA115436C2 (enExample)
WO (1) WO2013098755A2 (enExample)
ZA (1) ZA201405460B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
GB201406705D0 (en) 2014-04-15 2014-05-28 Univ Liverpool Fusion proteins,polynucleotides,expression vectors, and their uses
WO2016127346A1 (zh) * 2015-02-11 2016-08-18 四川大学华西医院 一种肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
CN107216385A (zh) * 2017-05-19 2017-09-29 何向锋 肿瘤特异性重组水蛭素及其制备方法和用途
CN109400711B (zh) * 2017-05-31 2022-02-08 四川大学华西医院 一种PDGFRβ靶向性肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
US11633363B2 (en) * 2017-09-27 2023-04-25 Emory University Fusion proteins having a toxin and cancer marker, nanoparticles, and uses related thereto
CN111909275A (zh) * 2019-05-08 2020-11-10 上海大学 延长多肽药物循环半衰期的靶向载药体系及其构建方法
CN110669146B (zh) * 2019-10-24 2023-05-23 常州大学 一种可特异性阻断衔接蛋白Nck的结合位点用于预防肠道EPEC感染的活性肽
KR102659285B1 (ko) * 2020-08-11 2024-04-22 경북대학교 산학협력단 암세포 유래 엑소좀에 선택적으로 결합하는 펩타이드 및 이의 용도
CN114031673B (zh) * 2021-12-22 2023-09-22 杭州长龄生物科技有限公司 一种多肽及其制备方法
CN114605517B (zh) * 2022-05-12 2022-09-27 广东海洋大学 一种具有广谱抗癌作用的多肽lxp-7及其应用
CN116063389B (zh) * 2022-08-23 2023-07-07 广州医科大学 递送核酸药物的多肽载体、治疗肿瘤的核酸药物及其制备方法
EP4631515A1 (en) * 2024-04-12 2025-10-15 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Antitumor parasporin-2 derived toxins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2160909A1 (en) 1993-04-28 1994-11-10 Hagan Bayley Cell-targeted lytic pore-forming agents
AU708239B2 (en) 1995-06-29 1999-07-29 Immunex Corporation Cytokine that induces apoptosis
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
AU2003280921B2 (en) 2003-11-03 2007-09-13 Beijing Sunbio Biotech Co., Ltd. A recombinant protein with cancer suppression action, its encoding gene and use
CN1256347C (zh) * 2003-12-10 2006-05-17 中国人民解放军第二军医大学 激肽原第五结构域-肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
WO2007022157A2 (en) 2005-08-16 2007-02-22 Genentech, Inc. Apoptosis sensitivity to ap02l/trail by testing for 'galnac-t14 expression in cells/tissues
WO2009002947A2 (en) 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
GB0723059D0 (en) 2007-11-23 2008-01-02 Nat Univ Ireland Improved cytokine design
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
AU2009206212B2 (en) * 2008-01-24 2014-01-16 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Lytic domain fusion constructs and methods of making and using same
TW200950778A (en) 2008-05-14 2009-12-16 Genentech Inc Methods of using Apo2L/TRAIL to treat cancer

Similar Documents

Publication Publication Date Title
JP2015504052A5 (enExample)
SI2797950T1 (en) Fusion protein against cancer
HRP20211010T1 (hr) Kimerni i hibridni polipeptidi faktora viii-fc i postupci njihove upotrebe
CN103068842B (zh) 对胰岛素受体具有高活性的单链胰岛素激动剂
JP2018510622A5 (enExample)
JP2012505902A5 (enExample)
FI4176894T3 (fi) Kimeerisiä tekijä viii -proteiineja ja niiden käyttötarkoituksia
PH12013500050A1 (en) Anticancer fusion protein
HRP20190689T1 (hr) Muteini suznog lipokalina koji vežu il-4r alfa
JP2014510518A5 (enExample)
ME03709B (me) Fuzijski proteini
JP2015525217A5 (enExample)
FI3256579T3 (fi) Kysteiiniproteaasi
JP2018515088A5 (enExample)
JP2010522540A5 (enExample)
HRP20110714T1 (hr) Fuzijski proteini analoga glp-1
UA97953C2 (uk) Стабілізовані поліпептиди інсуліноподібного фактора росту
IL199263A (en) Glucagon peptide with enhanced solubility, pharmaceutical composition containing it and its uses for drug preparation
HRP20210635T1 (hr) Novi mutant humanog seruma albumina
EA036805B8 (ru) Белок cd24 для подавления ответа хозяина на damp
JP2014506450A5 (enExample)
CN106232616A (zh) 两亲性合成抗菌肽、其药物组合物及其用途
Rubin et al. Backbone-cyclized peptides: a critical review
JP2018538356A5 (enExample)
JP2015524403A5 (enExample)